RxDoctor Payments Data

Stacy Ferrell, APRN

Family · Jonesboro, LANPI 1770004236

Payments from drug & device makers

$832in general payments, 2019–2025

Across 50 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$146
  • Novo Nordisk$126
  • Astellas Pharma US Inc$94
  • AstraZeneca$70
  • Amgen$51
  • GSK$49
  • plus $295 from 14 others

What the payments were for

  • Food & beverage$73889%
  • Education$9411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$832 in reported general payments places this provider in the 55th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$26,651
Medicare patients
50
Services billed
3,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide129$133,782
OzempicSemaglutide81$79,782
FarxigaDapagliflozin Propanediol91$63,706
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$52,667
KerendiaFinerenone59$52,548
JanuviaSitagliptin Phosphate42$36,987
TrulicityDulaglutide29$34,685
EliquisApixaban30$25,953
JardianceEmpagliflozin18$25,205
EntrestoSacubitril/Valsartan30$25,172
LinzessLinaclotide44$23,977
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$18,747
Tresiba Flextouch U-200Insulin Degludec24$14,568
MyrbetriqMirabegron24$12,709
Victoza 3-PakLiraglutide12$10,596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$34$168,467158 claims
AstraZenecaFarxiga, Breztri Aerosphere$70$82,453116 claims
Novo NordiskOzempic$126$79,78281 claims
GSKTrelegy Ellipta$49$52,66774 claims
BayerKerendia$146$52,54859 claims
AbbVieLinzess, Synthroid$21$25,28464 claims
NovartisEntresto$46$25,17230 claims
Astellas Pharma US IncMyrbetriq$94$12,70924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,610 family providers in Louisiana.

Other family in Jonesboro

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →